Reviewing the bioequivalence study of the antidiabetic drug Semaglutide of MSN Laboratories, the Subject Expert Committee ...

Sun Pharma's clinical trial failure impacts SPARC stock, highlighting the challenges in derma-oncology research.

Drug major Cipla has received approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...

An annual review of clinical trials for Alzheimer's disease highlights a growing number of active trials—and drugs—in the ...

Shares of Sun Pharma Advanced Research Company Ltd (SPARC) plunged nearly 20% on Wednesday on the NSE, after the company ...

Sun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase ...

Sun Pharma’s phase 2 trials of SCD-044 to treat moderate to severe psoriasis and atopic dermatitis fails to meet primary endpoint: Our Bureau, Mumbai Wednesday, June 4, 2025, 11 ...

Shares of Sun Pharma Advanced Research Company (SPARC) shares crashed significantly on Wednesday after the company announced ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

At a panel at CTO West Coast, experts from biopharmaceutical companies outlined innovative strategies to shape the future of ...